SARS-CoV-2-specific Humoral and Cell-mediated Immune Responses after Immunization with Inactivated COVID-19 Vaccine in Kidney Transplant Recipients (CVIM 1 Study)

enthalten in: bioRxiv.org | 2021

by Bruminhent, J. | Sethaudom, C. | Chaumdee, P. | +10

Increased Autotaxin levels in severe COVID-19, correlating with IL-6 levels, endothelial dysfunction biomarkers, and impaired functions of dendritic cells

enthalten in: bioRxiv.org | 2021

by Nikitopoulou, I. | Fanidis, D. | Ntatsoulis, K. | +15

ISARIC Clinical Data Report issued: 14 July 2021

enthalten in: bioRxiv.org | 2021

by Baillie, J. | Baruch, J. | Beane, A. | +50

Minimum manufacturing costs, national prices and estimated global availability of new repurposed therapies for COVID-19

enthalten in: bioRxiv.org | 2021

by Wang, J. | Levi, J. | Ellis, L. | +1

Molecular Pathophysiology of Cardiac Injury and Cardiac Microthrombi in Fatal COVID-19: Insights from Clinico-histopathologic and Single Nuclei RNA Sequencing Analyses

enthalten in: bioRxiv.org | 2021

by Fukuma, N. | Hulke, M. | Brener, M. | +22

Blockade of Interleukin Seventeen (IL-17A) with Secukinumab in Hospitalized COVID-19 patients – the BISHOP study

enthalten in: bioRxiv.org | 2021

by Resende, G. | da Cruz Lage, R. | Lobê, S. | +13

Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxia: an international, randomized, blinded trial

enthalten in: bioRxiv.org | 2021

by Munch, M. | Myatra, S. | Tirupakuzhi Vijayaraghavan, B. | +76

Lung Epithelial Regulation of BCL2 Related Protein A1 (BCL2A1) by Coronaviruses (SARS-CoV) and Type I Interferon Signaling

enthalten in: bioRxiv.org | 2021

by Ramana, C.

What We Learned from COVID-19: From endotheliitis to treatment

enthalten in: bioRxiv.org | 2021

by Dirican, A. | Ildir, S. | Uzar, T. | +2

Endothelial cell-activating antibodies in COVID-19

enthalten in: bioRxiv.org | 2021

by Shi, H. | Zuo, Y. | Navaz, S. | +13